A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients

Inclusion Criteria: * Subjects must be an adult \>= 19 years * Subjects who are eligible to be treated with adalimumab for intestinal Behcet's disease in accordance with the approved label in Korea * Subjects provide written authorization form for use/disclose of personal health data prior to participating in this study Exclusion Criteria: * Subjects who are contraindicated to any anti-TNF agent * Female subjects who are pregnant or breast feeding * Subjects who are participating in other interventional clinical trials